Compound | Retention Time | MRM Transition | Initial Gradient Conditions | Final Gradient Conditions | HPLC Columna |
---|---|---|---|---|---|
min | |||||
Carbamazepine (C) | 2.3 | 237.09/194.20 | A/B (90:10) | A/B (10:90) | BDS Hypersil C18 50 × 2.1 mm, 5 μm |
Citalopram (Ci) | 3.0 | 325.26/109.40 | A/B (95:5) | A/B (10:90) | BDS Hypersil C18 50 × 2.1 mm, 5 μm |
Ganciclovir (G) | 2.2 | 256.18/152.10 | A/B (95:5) | A/B (10:90) | Aquasil C18 50 × 4.6 mm, 5 μm |
Metoclopramide (M) | 2.0 | 301.21/228.10 | A/B (90:10) | A/B (10:90) | BDS Hypersil C18 50 × 2.1 mm, 5 μm |
N-Desmethylclozapine (N) | 3.2 | 313.23/192.00 | A/B (95:5) | A/B (10:90) | BDS Hypersil C18 50 × 2.1 mm, 5 μm |
Quinidine (Q) | 3.0 | 325.00/160.00 | A/B (95:5) | A/B (10:90) | BDS Hypersil C18 50 × 2.1 mm, 5 μm |
Risperidone (R) | 2.5 | 411.20/191.30 | A/B (90:10) | A/B (10:90) | BDS Hypersil C18 50 × 2.1 mm, 5 μm |
9-OH-Risperidone (R9) | 2.4 | 427.25/206.80 | A/B (90:10) | A/B (10:90) | BDS Hypersil C18 50 × 2.1 mm, 5 μm |
Thiopental (T) | 3.8 | 241.04/101.00 | A/B (90:10) | A/B (10:90) | BDS Hypersil C18 50 × 2.1 mm, 5 μm |
MRM, multiple reaction monitoring.
A, 0.1% formic acid.
B, Acetonitrile/methanol/formic acid (49.95:49.95:0.1).
C, Acetonitrile/formic acid (99.9:0.1).
↵ a Thermo Fisher Scientific (Waltham, MA).